ReviewCancers2024
Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Head and neck squamous cell carcinoma: current and emerging therapeutic strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Deep learning-based computed tomography detection of early lymph node metastasis in head and neck cancer.Quantitative imaging in medicine and surgery · 2026Article
- Evaluation of serum Cytokeratin 5 and p63 as non-invasive biomarkers for the diagnosis and staging of cervical cancer: a case-control study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Hydrogels in head and neck cancer: Innovations and translational advances in research and therapy.Biomaterials · 2026Review
- Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma.Journal of visualized experiments : JoVE · 2026Article
- Therapeutic efficacy of external beam radiotherapy combined with anti-PD-L1 inhibition in a preclinical syngeneic head and neck cancer model.Clinical and translational radiation oncology · 2026Article
- Next-generation immunotherapies for head and neck squamous cell carcinoma: targeting novel immune checkpoints.Annals of medicine · 2025Review
- MicroRNAs as Emerging Therapeutic Targets Modulating the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma.International journal of molecular sciences · 2025Review
- Single-Cell Transcriptomics Identifies Novel Prognostic Signatures in HNSCC Immunotherapy Response.Cancer science · 2025Article
- Towards a Less Invasive Treatment for Head and Neck Cancer: Initial Evaluation of Gold Nanoparticle-Mediated Photothermal Therapy.Pharmaceutics · 2025Article
- Patient-Reported Symptoms and Direct Health Care Costs in Head and Neck Cancer.JAMA otolaryngology-- head & neck surgery · 2025Article
- Molecular Targets for Pharmacotherapy of Head and Neck Squamous Cell Carcinomas.Current issues in molecular biology · 2025Review
- Unraveling the Role of Tumor-Infiltrating Immune Cells in Head and Neck Squamous Cell Carcinoma: Implications for Antitumor Immune Responses and Immunotherapy.International journal of molecular sciences · 2025Review
- ADORA2B promotes proliferation and migration in head and neck squamous cell carcinoma and is associated with immune infiltration.BMC cancer · 2025Article
- Article
- Article
- Nanotechnology in the perioperative treatment of head and neck cancer: application and outlook.Frontiers in bioengineering and biotechnology · 2025Review
- C16orf74 is a novel prognostic biomarker and associates with immune infiltration in head and neck squamous cell carcinoma.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) is a complex cancer requiring a multidisciplinary approach. For patients with locally or regionally advanced disease, surgery and/or radiation are the cornerstones of definitive treatment. Medical therapy plays an important adjunct role in this setting, typically consisting of a platinum-based regimen given as induction, concurrent, or adjuvant treatment. While relapsed/metastatic HNSCC has historically been a difficult-to-treat disease with poor outcomes, options have considerably improved with the incorporation of biologics and immune checkpoint inhibitors. Clinical trials are ongoing to investigate novel approaches, including new and combination immunotherapies, targeted therapies, therapeutic vaccines, antibody-drug conjugates, and cellular therapies. The results thus far have been mixed, highlighting the knowledge gaps that continue to challenge the medical oncologist treating HNSCC. Here, we present the most updated and broad review of the current treatment landscape in both locoregional and metastatic HNSCC and discuss the expansive future medical therapies under investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.